29602-15-1

Usage

Appearance

Yellow crystalline solid

Uses

Reagent in organic synthesis
Precursor in the production of pharmaceuticals and dyes

Chemical reactions

Reduction
Oxidation
Condensation

Versatility

Versatile compound in organic chemistry

Preparation

Used in the preparation of heterocycles

Synthesis

Key intermediate in the synthesis of biologically active compounds

Pharmacological properties

Studied for potential anti-inflammatory and anti-microbial activities

InChI:InChI=1/C14H12N2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H,15-16H2

Upstream product

• 7664-41-7 ammonia 
• 6067-45-4 4,4'-dinitrobenzil 
• 122-85-0 para-acetamidobenzaldehyde 
• 5702-73-8 (+/-)-4.4'-Bis-acetamino-benzoin 

Downstream Products

• 855293-17-3 4,4'-diamino-benzoin 
• 875875-69-7 N-acetyl-sulfanilic acid-[6,7-bis-(4-amino-phenyl)-4-oxo-3,4-dihydro-pteridin-2-ylamide] 
• 21501-14-4 4,4-bis(acetylamino)benzil 
• 2810-93-7 4,4'-quinoxaline-2,3-diyl-bis-aniline 

Relevant academic research and scientific papers

Turn-On Mode Fluorescence Switch by Using Negative Photochromic Imidazole Dimer

The development of fluorescence switchable molecules in several polar and apolar environments has been required for fluorescence imaging of nanostructures. Photochromic molecules are an important class for the reversible light-triggered fluorescence switc

Combination therapy

The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.